Roozbeh Tarighati Rasekhi

Dr. Roozbeh Tarighati Rasekhi

Emory University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Life Sciences
Verified
Journal Article
Closed access
SBSavalan Babapoor
Savalan Babapoor
DGDeanna Gill
Deanna Gill
JWJackson Walker
Jackson Walker
RRRoozbeh Tarighati Rasekhi
Roozbeh Tarighati Rasekhi
BBBehnam Bozorgnia
Behnam Bozorgnia
AAAman Amanullah
Aman Amanullah

Verified
Journal Article
Open access
PDF file
SZSareh Zhand
Sareh Zhand
MJMarie Saghaeian Jazi
Marie Saghaeian Jazi
Saeed MohammadiSaeed Mohammadi
Saeed Mohammadi
RRRoozbeh Tarighati Rasekhi
Roozbeh Tarighati Rasekhi
GRGhassem Rostamian
Ghassem Rostamian
Mark William DouglasMark William Douglas
Mark William Douglas
The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US Food and Drug Administration (FDA) approved for emergency use in adults and children hospitalized with severe suspected or laboratory-confirmed COVID-19. Herein we summarize the general features of SARS-CoV-2’s molecular and immune pathogenesis and discuss available pharmacological strategies, based on our present understanding of SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently in progress to investigate the efficacy of potential therapies for COVID-19.